{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:04:55Z","timestamp":1788908695793,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00198-026-07862-5","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:37:04Z","timestamp":1769762224000},"page":"927-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypocalcemia following denosumab in osteoporosis: Incidence and risk factors in a Saudi cohort"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-4276","authenticated-orcid":false,"given":"Kousalya","family":"Prabahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouf M.","family":"Alharthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"AlKenani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"7862_CR1","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/TCRM.S138000","volume":"14","author":"F Pouresmaeili","year":"2018","unstructured":"Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM (2018) A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag 14:2029\u20132049. https:\/\/doi.org\/10.2147\/TCRM.S138000","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"7862_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"issue":"1","key":"7862_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7 (2017) An overview and management of osteoporosis. Eur J Rheumatol. 4(1):46\u201356. https:\/\/doi.org\/10.5152\/eurjrheum.2016.048","journal-title":"Eur J Rheumatol."},{"issue":"1","key":"7862_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16(1):609. https:\/\/doi.org\/10.1186\/s13018-021-02772-0","journal-title":"J Orthop Surg Res"},{"key":"7862_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/PPA.S46192","volume":"8","author":"T Miyazaki","year":"2014","unstructured":"Miyazaki T, Tokimura F, Tanaka S (2014) A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence 8:463\u2013471. https:\/\/doi.org\/10.2147\/PPA.S46192","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"7862_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39(1):58\u201374. https:\/\/doi.org\/10.1007\/s12325-021-01936-y","journal-title":"Adv Ther"},{"issue":"8","key":"7862_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"12","key":"7862_CR8","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26(12):2773\u20132783. https:\/\/doi.org\/10.1007\/s00198-015-3234-7","journal-title":"Osteoporos Int"},{"issue":"9886","key":"7862_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886):50\u201356. https:\/\/doi.org\/10.1016\/S0140-6736(13)60856-9","journal-title":"Lancet"},{"issue":"1","key":"7862_CR10","doi-asserted-by":"publisher","first-page":"e12420","DOI":"10.7759\/cureus.12420","volume":"13","author":"M Tinawi","year":"2021","unstructured":"Tinawi M (2021) Disorders of calcium metabolism: hypocalcemia and hypercalcemia. Cureus 13(1):e12420. https:\/\/doi.org\/10.7759\/cureus.12420","journal-title":"Cureus"},{"key":"7862_CR11","doi-asserted-by":"publisher","first-page":"117863882312236","DOI":"10.1177\/11786388231223604","volume":"17","author":"ZI Bitar","year":"2024","unstructured":"Bitar ZI, Hajjiah AM, Maadarani OS et al (2024) Hypocalcemia in patients with osteoporosis and normal renal function, treated with denosumab, a retrospective analysis. Nutr Metab Insights 17:11786388231223604. https:\/\/doi.org\/10.1177\/11786388231223604","journal-title":"Nutr Metab Insights"},{"issue":"7","key":"7862_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"7862_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.4804","volume":"38","author":"A Cowan","year":"2023","unstructured":"Cowan A, Jeyakumar N, McArthur E et al (2023) Hypocalcemia risk of denosumab across the spectrum of kidney disease: a population-based cohort study. J Bone Miner Res 38(5):650\u2013658. https:\/\/doi.org\/10.1002\/jbmr.4804","journal-title":"J Bone Miner Res"},{"issue":"8","key":"7862_CR14","doi-asserted-by":"publisher","first-page":"e234508","DOI":"10.1136\/bcr-2020-234508","volume":"13","author":"N Daga","year":"2020","unstructured":"Daga N, Joseph F (2020) Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency. BMJ Case Rep 13(8):e234508. https:\/\/doi.org\/10.1136\/bcr-2020-234508","journal-title":"BMJ Case Rep"},{"key":"7862_CR15","doi-asserted-by":"publisher","first-page":"17021","DOI":"10.1038\/boneres.2017.21","volume":"5","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Suzuki T, Kamimura M et al (2017) Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res 5:17021. https:\/\/doi.org\/10.1038\/boneres.2017.21","journal-title":"Bone Res"},{"issue":"4S","key":"7862_CR16","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) Kdigo 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"1","key":"7862_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00198-023-06926-0","volume":"35","author":"A Sp\u00e5ngeus","year":"2024","unstructured":"Sp\u00e5ngeus A, Rydetun J, Woisetschl\u00e4ger M (2024) Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection. Osteoporos Int 35(1):173\u2013180. https:\/\/doi.org\/10.1007\/s00198-023-06926-0","journal-title":"Osteoporos Int"},{"issue":"4","key":"7862_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","volume":"31","author":"G Tsvetov","year":"2020","unstructured":"Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T (2020) Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int 31(4):655\u2013665. https:\/\/doi.org\/10.1007\/s00198-019-05261-7","journal-title":"Osteoporos Int"},{"key":"7862_CR19","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S123172","volume":"12","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Nagai T, Sakamoto K et al (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. TCRM 12:1831\u20131840. https:\/\/doi.org\/10.2147\/TCRM.S123172","journal-title":"TCRM"},{"issue":"3","key":"7862_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00774-020-01180-4","volume":"39","author":"S Tanaka","year":"2021","unstructured":"Tanaka S, Mizutani H, Tsuruya E, Fukuda R, Kuge K, Okubo N (2021) Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. J Bone Miner Metab 39(3):463\u2013473. https:\/\/doi.org\/10.1007\/s00774-020-01180-4","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"7862_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ajco.12517","volume":"13","author":"K Pittman","year":"2017","unstructured":"Pittman K, Antill YC, Goldrick A, Goh J, de Boer RH (2017) Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac J Clin Oncol 13(4):266\u2013276. https:\/\/doi.org\/10.1111\/ajco.12517","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"7862_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/cen.14169","volume":"92","author":"LH Lau","year":"2020","unstructured":"Lau LH, Cliff ERS, Wong V et al (2020) Hypocalcaemia following denosumab in prostate cancer: a clinical review. Clin Endocrinol (Oxf) 92(6):495\u2013502. https:\/\/doi.org\/10.1111\/cen.14169","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"13","key":"7862_CR23","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","volume":"51","author":"JJ Body","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH et al (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 51(13):1812\u20131821. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.016","journal-title":"Eur J Cancer"},{"issue":"11","key":"7862_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.4045","volume":"25","author":"ALH Huynh","year":"2016","unstructured":"Huynh ALH, Baker ST, Stewardson AJ, Johnson DF (2016) Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharm Drug Saf 25(11):1274\u20131278. https:\/\/doi.org\/10.1002\/pds.4045","journal-title":"Pharm Drug Saf"},{"issue":"26_suppl","key":"7862_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/jco.2014.32.26_suppl.144","volume":"32","author":"SA Trevino Manllo","year":"2014","unstructured":"Trevino Manllo SA, Khalon P, Thind R, Bhatia R, Ali HY (2014) Evaluation of risk factors associated with denosumab induced hypocalcemia. J Clin Oncol 32(26_suppl):144\u2013144. https:\/\/doi.org\/10.1200\/jco.2014.32.26_suppl.144","journal-title":"J Clin Oncol"},{"issue":"1","key":"7862_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1365-2362.2003.01103.x","volume":"33","author":"L Rejnmark","year":"2003","unstructured":"Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L (2003) Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest 33(1):41\u201350. https:\/\/doi.org\/10.1046\/j.1365-2362.2003.01103.x","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"7862_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.semnephrol.2011.09.008","volume":"31","author":"M Grieff","year":"2011","unstructured":"Grieff M, Bushinsky DA (2011) Diuretics and disorders of calcium homeostasis. Semin Nephrol 31(6):535\u2013541. https:\/\/doi.org\/10.1016\/j.semnephrol.2011.09.008","journal-title":"Semin Nephrol"},{"issue":"10","key":"7862_CR28","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL et al (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07862-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07862-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07862-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:26:55Z","timestamp":1779290815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-07862-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7862"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07862-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kousalya Prabahar, Nouf Alharthi, and Rola AlKenani declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of King Fahad Medical City, Riyadh, Saudi Arabia (H-01-R-012).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"The requirement for patient consent was waived because the data were collected from hospital records.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}